Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ischemic Heart Disease

Free Subscription Articles published in J Clin Endocrinol Metab Retrieve available abstracts of 50 articles: HTML format

Single Articles

September 2025
1. MEHRI HAJMIR M, Sayoldin B, Rahnavard A, Barberio MD, et al
   Plasma branched-chain amino acid and cardiovascular disease risk factors: a longitudinal analysis of a lifestyle trial.
   J Clin Endocrinol Metab. 2025 Sep 16:dgaf509. doi: 10.1210.
   PubMed     Abstract available
   
   
   August 2025
2. BJORNSDOTTIR S, Mannstadt M, Clarke B, Spelman T, et al
   Response to Letter to the Editor From Hasebe and Su: "Higher risk of cardiovascular diseases in patients with chronic hypoparathyroidism in Sweden".
   J Clin Endocrinol Metab. 2025 Aug 25:dgaf475. doi: 10.1210.
   PubMed    
   
   
   
3. HASEBE M, Su CY
   Letter to the Editor from Hasebe and Su: "Increased Risk of Cardiovascular Diseases in Patients With Chronic Hypoparathyroidism in Sweden".
   J Clin Endocrinol Metab. 2025 Aug 25:dgaf474. doi: 10.1210.
   PubMed    
   
   
   July 2025
4. LONG X
   Letter to the Editor from Long: "Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom Population (ACEL-UK): Cohort Study".
   J Clin Endocrinol Metab. 2025 Jul 21:dgaf419. doi: 10.1210.
   PubMed    
   
   
   June 2025
5. XU H, Lu Y
   Letter to the editor from Xu and Lu: "Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank".
   J Clin Endocrinol Metab. 2025 Jun 26:dgaf379. doi: 10.1210.
   PubMed    
   
   
   May 2025
6. LU X, Zhu X, Li G, Wu L, et al
   Habitual Coffee, Tea, and Caffeine Consumption, Circulating Metabolites, and the Risk of Cardiometabolic Multimorbidity.
   J Clin Endocrinol Metab. 2025;110:e1845-e1855.
   PubMed     Abstract available
   
   
   
7. POHLMAN N, Patel PN, Essien UR, Tang JJ, et al
   Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.
   J Clin Endocrinol Metab. 2025 May 19:dgaf295. doi: 10.1210.
   PubMed     Abstract available
   
   
   April 2025
8. BJORNSDOTTIR S, Mannstadt M, Clarke B, Spelman T, et al
   Increased risk of cardiovascular diseases in patients with chronic hypoparathyroidism in Sweden.
   J Clin Endocrinol Metab. 2025 Apr 28:dgaf257. doi: 10.1210.
   PubMed     Abstract available
   
   
   
9. HOLLEY M, Razvi S, Maxwell I, Dew R, et al
   Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom population (ACEL-UK): Cohort Study.
   J Clin Endocrinol Metab. 2025 Apr 3:dgaf208. doi: 10.1210.
   PubMed     Abstract available
   
   
   
10. TELES BSBS, Ramalho SHR, Bittencourt MS, Bensenor IM, et al
    Plasma levels of small HDL particles are associated with coronary atherosclerosis progression in adults with diabetes.
    J Clin Endocrinol Metab. 2025 Apr 3:dgaf215. doi: 10.1210.
    PubMed     Abstract available
    
    
    March 2025
11. BENE-ALHASAN Y, Shitole SG, Buzkova P, Hirsch CH, et al
    Non-Esterified Fatty Acid Profiles and Cause-Specific Mortality: The Cardiovascular Health Study.
    J Clin Endocrinol Metab. 2025 Mar 24:dgaf182. doi: 10.1210.
    PubMed     Abstract available
    
    
    
12. MITA T, Osonoi Y, Someya Y, Osonoi T, et al
    Relationship of carbohydrate intake proportion to cardiovascular events in Japanese people with type 2 diabetes mellitus.
    J Clin Endocrinol Metab. 2025 Mar 21:dgaf179. doi: 10.1210.
    PubMed     Abstract available
    
    
    
13. SONAWALLA A, Chasman DI, Chan YM
    Age at Menarche and Coronary Artery Disease Risk: Divergent Associations with Different Sources of Variation.
    J Clin Endocrinol Metab. 2025 Mar 10:dgaf141. doi: 10.1210.
    PubMed     Abstract available
    
    
    
14. NISHIO Y
    Does Insulin Work as Good One or Bad One for the Cardiovascular Tissues?
    J Clin Endocrinol Metab. 2025 Mar 7:dgaf051. doi: 10.1210.
    PubMed    
    
    
    February 2025
15. HSIAO YY, Chen YY, Kuo MJ, Chien YS, et al
    SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study.
    J Clin Endocrinol Metab. 2025 Feb 25:dgae861. doi: 10.1210.
    PubMed     Abstract available
    
    
    
16. 
    Correction to: "Associations Between Subclinical Thyroid Dysfunction and Cardiovascular Risk Factors According to Age and Sex".
    J Clin Endocrinol Metab. 2025 Feb 11:dgaf061. doi: 10.1210.
    PubMed    
    
    
    
17. JIANG L, Zhou L, Liu J, Wang Y, et al
    Sex Differences in the Association Between Thyroid Hormone Sensitivity and Cardiovascular-Kidney-Metabolic Syndrome.
    J Clin Endocrinol Metab. 2025 Feb 4:dgaf059. doi: 10.1210.
    PubMed     Abstract available
    
    
    January 2025
18. CHOE HJ, Choi YM, Ha Y, Kim J, et al
    The Role of the Parametric Thyroid Feedback Quantile Index in Cardiovascular Risk Evaluation Among Euthyroid Koreans.
    J Clin Endocrinol Metab. 2025 Jan 22:dgaf046. doi: 10.1210.
    PubMed     Abstract available
    
    
    
19. AN J, Zhang S, Cheng X, Jia C, et al
    The Association between Serum Polychlorinated Biphenyls and Incident Cardiovascular Disease among Type 2 Diabetes.
    J Clin Endocrinol Metab. 2025 Jan 15:dgaf014. doi: 10.1210.
    PubMed     Abstract available
    
    
    
20. WANG S, Zhang Y, Balati A, Li B, et al
    Effect of Sodium-Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
    J Clin Endocrinol Metab. 2025 Jan 15:dgaf016. doi: 10.1210.
    PubMed     Abstract available
    
    
    December 2024
21. 
    Correction to: "Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study".
    J Clin Endocrinol Metab. 2024 Dec 17:dgae870. doi: 10.1210.
    PubMed    
    
    
    
22. BARETELLA O, Blum MR, Abolhassani N, Alwan H, et al
    Associations between subclinical thyroid dysfunction and cardiovascular risk factors according to age and sex.
    J Clin Endocrinol Metab. 2024 Dec 12:dgae860. doi: 10.1210.
    PubMed     Abstract available
    
    
    
23. AZIZI M, Riancho J, Amar L
    Aldosterone synthase inhibitors: a potential revival for treatment of renal and cardiovascular diseases.
    J Clin Endocrinol Metab. 2024 Dec 4:dgae823. doi: 10.1210.
    PubMed     Abstract available
    
    
    November 2024
24. SHI B, Liu Z, Zhang R, Tiemuerniyazi X, et al
    Subclinical hypothyroidism as an independent predictor of cardiovascular prognosis in left ventricular thrombus patients.
    J Clin Endocrinol Metab. 2024 Nov 11:dgae793. doi: 10.1210.
    PubMed     Abstract available
    
    
    September 2024
25. LEBLANC E, Brooks N, Davies M, Chatterjee R, et al
    Sex-specific Cardiovascular Risk Factors and Treatment in Females with T2DM and CVD: Developments and Knowledge Gaps.
    J Clin Endocrinol Metab. 2024 Sep 23:dgae655. doi: 10.1210.
    PubMed     Abstract available
    
    
    
26. GEORGIOPOULOS G, Athanasopoulos S, Mavraganis G, Konstantaki C, et al
    Incremental value of blood-based markers of liver fibrosis in cardiovascular risk stratification.
    J Clin Endocrinol Metab. 2024 Sep 11:dgae619. doi: 10.1210.
    PubMed     Abstract available
    
    
    
27. PAQUETTE M, Trinder M, Guay SP, Brunham LR, et al
    Predictors of cardiovascular disease in individuals with dysbetalipoproteinemia: a prospective study in the UK Biobank.
    J Clin Endocrinol Metab. 2024 Sep 7:dgae618. doi: 10.1210.
    PubMed     Abstract available
    
    
    August 2024
28. YANG C, Ji L, Han X
    Low C reactive protein-alleles in hepatocyte nuclear factor 1A are associated with an increased risk of cardiovascular disease: a Meta-analysis.
    J Clin Endocrinol Metab. 2024 Aug 30:dgae602. doi: 10.1210.
    PubMed     Abstract available
    
    
    
29. CHENG W, Geng S, Li Y, Chen R, et al
    Sex Differences in 'Life's Essential 8' cardiovascular health and Type 2 Diabetes Mellitus Risk Across Menopause Stages.
    J Clin Endocrinol Metab. 2024 Aug 16:dgae557. doi: 10.1210.
    PubMed     Abstract available
    
    
    
30. ABU IRSHEED G, Martyn-Nemeth P, Baron KG, Reutrakul S, et al
    Sleep disturbances in type 1 diabetes and mitigating cardiovascular risk.
    J Clin Endocrinol Metab. 2024 Aug 6:dgae539. doi: 10.1210.
    PubMed     Abstract available
    
    
    July 2024
31. YOUNIS JS, Taylor HS
    Is there an Association between Endometriosis, Early Menopause, and Cardiovascular Disease?
    J Clin Endocrinol Metab. 2024 Jul 31:dgae508. doi: 10.1210.
    PubMed     Abstract available
    
    
    
32. HEIANZA Y, Tiwari S, Wang X, Watrous JD, et al
    Gut-Microbiota-Related Metabolite Phenylacetylglutamine and Risk of Incident Coronary Heart Disease among Women.
    J Clin Endocrinol Metab. 2024 Jul 30:dgae525. doi: 10.1210.
    PubMed     Abstract available
    
    
    
33. SONG DK, Oh J, Sung YA, Hong YS, et al
    All-cause mortality and incidence of cardiovascular diseases in lean patients with newly diagnosed type 2 diabetes.
    J Clin Endocrinol Metab. 2024 Jul 26:dgae449. doi: 10.1210.
    PubMed     Abstract available
    
    
    
34. HENNEY AE, Gillespie CS, Lai JYM, Schofield P, et al
    Risk of type 2 diabetes, MASLD and cardiovascular disease in people living with polycystic ovary syndrome.
    J Clin Endocrinol Metab. 2024 Jul 11:dgae481. doi: 10.1210.
    PubMed    
    
    
    June 2024
35. CHAROENSRI S, Auchus RJ
    Response to Letter to the Editor From Tang and Zhang: "Predictors of Cardiovascular Morbidities in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia".
    J Clin Endocrinol Metab. 2024 Jun 26:dgae402. doi: 10.1210.
    PubMed    
    
    
    
36. TANG C, Zhang S
    Letter to the Editor From Tang and Zhang: "Predictors of Cardiovascular Morbidities in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia".
    J Clin Endocrinol Metab. 2024 Jun 26:dgae401. doi: 10.1210.
    PubMed    
    
    
    May 2024
37. STOKAR J, Szalat A
    Response to Letter to the Editor from Kawaguchi: 'Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study.
    J Clin Endocrinol Metab. 2024 May 20:dgae348. doi: 10.1210.
    PubMed    
    
    
    
38. KAWAGUCHI H
    Letter to the Editor from Kawaguchi: 'Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study'.
    J Clin Endocrinol Metab. 2024 May 18:dgae347. doi: 10.1210.
    PubMed    
    
    
    
39. FARR JN
    Cardiovascular Safety and Romosozumab - The Plot Thickens.
    J Clin Endocrinol Metab. 2024 May 8:dgae313. doi: 10.1210.
    PubMed    
    
    
    April 2024
40. KAJIKAWA M, Maruhashi T, Kishimoto S, Yamaji T, et al
    A Body Shape Index as a Simple Anthropometric Marker of Abdominal Obesity and Risk of Cardiovascular Events.
    J Clin Endocrinol Metab. 2024 Apr 25:dgae282. doi: 10.1210.
    PubMed     Abstract available
    
    
    
41. ZHANG G, Jiang W, He F, Fu J, et al
    LDL-C and TC mediate the risk of PNPLA3 inhibition on cardiovascular diseases.
    J Clin Endocrinol Metab. 2024 Apr 18:dgae264. doi: 10.1210.
    PubMed     Abstract available
    
    
    
42. CHE J, He N, Kuang X, Zheng C, et al
    Dietary n-3 fatty acids intake and all-cause and cardiovascular mortality in patients with pre-diabetes and diabetes.
    J Clin Endocrinol Metab. 2024 Apr 16:dgae265. doi: 10.1210.
    PubMed     Abstract available
    
    
    
43. SONG X, Xiong L, Guo T, Chen X, et al
    Cystatin C is a predictor for long-term All-Cause and Cardiovascular Mortality in US Adults with Metabolic Syndrome.
    J Clin Endocrinol Metab. 2024 Apr 10:dgae225. doi: 10.1210.
    PubMed     Abstract available
    
    
    March 2024
44. QIU Z, Lee DH, Lu Q, Li R, et al
    Associations of Regional Body Fat with Risk of Cardiovascular Disease and Mortality among Individuals with Type 2 Diabetes.
    J Clin Endocrinol Metab. 2024 Mar 26:dgae192. doi: 10.1210.
    PubMed     Abstract available
    
    
    
45. VAN DER VALK ES, Mohseni M, Iyer AM, van den Hurk M, et al
    Long-term glucocorticoid exposure and incident cardiovascular diseases - the Lifelines cohort.
    J Clin Endocrinol Metab. 2024 Mar 19:dgae081. doi: 10.1210.
    PubMed     Abstract available
    
    
    
46. STOKAR J, Szalat A
    Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study.
    J Clin Endocrinol Metab. 2024 Mar 14:dgae173. doi: 10.1210.
    PubMed     Abstract available
    
    
    
47. COSTA FC, Gomes LG, de Lima TM, Bortolotto LA, et al
    Cardiovascular risk in women with nonclassical congenital adrenal hyperplasia.
    J Clin Endocrinol Metab. 2024 Mar 11:dgae155. doi: 10.1210.
    PubMed     Abstract available
    
    
    February 2024
48. CHEN GC, Hukportie DN, Liu YJ, Wang HP, et al
    Microvascular Disease, Cardiovascular Health, and Risk of Coronary Heart Disease in Type 2 Diabetes: A UK Biobank Study.
    J Clin Endocrinol Metab. 2024 Feb 27:dgae100. doi: 10.1210.
    PubMed     Abstract available
    
    
    January 2024
49. PARK SY, Jun JE, Jeong IK, Ahn KJ, et al
    Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes.
    J Clin Endocrinol Metab. 2024 Jan 4:dgad714. doi: 10.1210.
    PubMed     Abstract available
    
    
    October 2023
50. HIRSCHBERG AL
    Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women-What Is the Evidence?
    J Clin Endocrinol Metab. 2023 Oct 27:dgad590. doi: 10.1210.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge.